- Home
- IVA vs GNTA Comparison
IVA vs GNTA Comparison
Compare IVA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- GNTA
- Stock Information
- Founded
- IVA 2011
- GNTA 2014
- Country
- IVA France
- GNTA Italy
- Employees
- IVA N/A
- GNTA N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVA Health Care
- GNTA Health Care
- Exchange
- IVA Nasdaq
- GNTA Nasdaq
- Market Cap
- IVA 117.3M
- GNTA 96.9M
- IPO Year
- IVA 2020
- GNTA 2021
- Fundamental
- Price
- IVA $2.51
- GNTA $4.80
- Analyst Decision
- IVA Strong Buy
- GNTA Strong Buy
- Analyst Count
- IVA 4
- GNTA 1
- Target Price
- IVA $14.00
- GNTA $25.00
- AVG Volume (30 Days)
- IVA 28.6K
- GNTA 7.4K
- Earning Date
- IVA 09-25-2024
- GNTA 01-01-0001
- Dividend Yield
- IVA N/A
- GNTA N/A
- EPS Growth
- IVA N/A
- GNTA N/A
- EPS
- IVA N/A
- GNTA N/A
- Revenue
- IVA $20,652,523.00
- GNTA N/A
- Revenue This Year
- IVA N/A
- GNTA N/A
- Revenue Next Year
- IVA $361.78
- GNTA N/A
- P/E Ratio
- IVA N/A
- GNTA N/A
- Revenue Growth
- IVA N/A
- GNTA N/A
- 52 Week Low
- IVA $1.53
- GNTA $2.20
- 52 Week High
- IVA $4.75
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- IVA 45.32
- GNTA 46.40
- Support Level
- IVA $2.52
- GNTA $4.44
- Resistance Level
- IVA $2.77
- GNTA $5.20
- Average True Range (ATR)
- IVA 0.13
- GNTA 0.44
- MACD
- IVA -0.03
- GNTA -0.04
- Stochastic Oscillator
- IVA 0.00
- GNTA 34.29
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.